跳至主要内容
临床试验/NCT03496844
NCT03496844已完成不适用

A Pilot Study of F-18 Fluciclovine-PET/CT as A Diagnostic Tool for Bone Metastases in Patients With Hormonal Sensitive and Resistant Prostate Adenocarcinoma

University of Arizona2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2018年4月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
15
试验地点
2
主要终点
True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy

研究概览

简要总结

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Be ≥ 18 years of age
  • Diagnosed with prostate cancer
  • Be willing and able to provide informed consent
  • Be informed of the investigational nature of this study

排除标准

  • Having a history of severe claustrophobia
  • Weight exceeding 400lbs

结局指标

主要结局

True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy

时间窗: 1 year

True positive and false positive rates of positive findings in the skeleton on F-18 fluciclovine-PET/CT scan compared to gold standard pathology from bone biopsy

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验